NEW YORK (GenomeWeb News) – Singapore cancer diagnostics firm Clearbridge BioMedics announced on Wednesday the closing of a Series B financing round, bringing in S$9.0 million (US$7.2 million).

The financing will be used to further develop Clearbridge's ClearCell System, a non-biomarker-based platform for detecting, isolating, and retrieving circulating tumor cells from blood. The system consists of the ClearCell unit and single-use microfluidic biochips called CTChips.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.